Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac cause of systemic embolism and cardioembolic stroke. The risk of thromboembolic complications increases significantly when performing for electrical cardioversion. Vitamin K antagonists (warfarin) more often used to prepare for electrical cardiover...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2016-11-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1341 |
| _version_ | 1797232245695578112 |
|---|---|
| author | N. A. Novikova A. N. Volovchenko |
| author_facet | N. A. Novikova A. N. Volovchenko |
| author_sort | N. A. Novikova |
| collection | DOAJ |
| description | Atrial fibrillation (AF) is the most common cardiac cause of systemic embolism and cardioembolic stroke. The risk of thromboembolic complications increases significantly when performing for electrical cardioversion. Vitamin K antagonists (warfarin) more often used to prepare for electrical cardioversion. However lately new oral anticoagulants (NOAC) are becoming more common for the prevention of thromboembolic events in patients with AF. Possibility to perform planned cardioversion while receiving dabigatran has been shown in a retrospective analysis of patients from the RE-LY study. The incidence of stroke and systemic embolism within 30 days after cardioversion was low and did not differ significantly in all groups. Thus, the results of the RE-LY study allow performing the planned and emergency cardioversion in patients receiving dabigatran. These results were later confirmed in other retrospective studies and meta-analyzes that are presented in this article. The X-VERT study and sub-analysis of the ARISTOTLE study showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical cardioversion in patients with non-valvular AF. Long-term preparation courses for the cardioversion were used in the majority of patients in all published papers. By the present time a specially designed study directly aimed at assessing the NOAC effectiveness, in particular, dabigatran, in preparing and performing electrical cardioversion was not carried out in patients with AF. Some questions about the safety and efficacy of dabigatran during short preparation courses before electrical cardioversion remain. |
| first_indexed | 2024-03-08T14:03:20Z |
| format | Article |
| id | doaj.art-a69a3f4de8274935acf0154e5529ba66 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-04-24T15:57:13Z |
| publishDate | 2016-11-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-a69a3f4de8274935acf0154e5529ba662024-04-01T07:43:34ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-11-0112559059410.20996/1819-6446-2016-12-5-590-5941267Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial FibrillationN. A. Novikova0A. N. Volovchenko1I.M. Sechenov First Moscow State Medical University. Trubetskaya ul. 8-2, Moscow, 119991 RussiaI.M. Sechenov First Moscow State Medical University. Trubetskaya ul. 8-2, Moscow, 119991 RussiaAtrial fibrillation (AF) is the most common cardiac cause of systemic embolism and cardioembolic stroke. The risk of thromboembolic complications increases significantly when performing for electrical cardioversion. Vitamin K antagonists (warfarin) more often used to prepare for electrical cardioversion. However lately new oral anticoagulants (NOAC) are becoming more common for the prevention of thromboembolic events in patients with AF. Possibility to perform planned cardioversion while receiving dabigatran has been shown in a retrospective analysis of patients from the RE-LY study. The incidence of stroke and systemic embolism within 30 days after cardioversion was low and did not differ significantly in all groups. Thus, the results of the RE-LY study allow performing the planned and emergency cardioversion in patients receiving dabigatran. These results were later confirmed in other retrospective studies and meta-analyzes that are presented in this article. The X-VERT study and sub-analysis of the ARISTOTLE study showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical cardioversion in patients with non-valvular AF. Long-term preparation courses for the cardioversion were used in the majority of patients in all published papers. By the present time a specially designed study directly aimed at assessing the NOAC effectiveness, in particular, dabigatran, in preparing and performing electrical cardioversion was not carried out in patients with AF. Some questions about the safety and efficacy of dabigatran during short preparation courses before electrical cardioversion remain.https://www.rpcardio.online/jour/article/view/1341atrial fibrillationelectrical cardioversionwarfarindabigatran |
| spellingShingle | N. A. Novikova A. N. Volovchenko Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation Рациональная фармакотерапия в кардиологии atrial fibrillation electrical cardioversion warfarin dabigatran |
| title | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation |
| title_full | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation |
| title_fullStr | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation |
| title_full_unstemmed | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation |
| title_short | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation |
| title_sort | dabigatran etexilate in the course of electrical cardioversion in patients with non valvular atrial fibrillation |
| topic | atrial fibrillation electrical cardioversion warfarin dabigatran |
| url | https://www.rpcardio.online/jour/article/view/1341 |
| work_keys_str_mv | AT nanovikova dabigatranetexilateinthecourseofelectricalcardioversioninpatientswithnonvalvularatrialfibrillation AT anvolovchenko dabigatranetexilateinthecourseofelectricalcardioversioninpatientswithnonvalvularatrialfibrillation |